Seres Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MCRB and other ETFs, options, and stocks.

About MCRB

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. 

CEO
Thomas J. DesRosier
CEOThomas J. DesRosier
Employees
103
Employees103
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2010
Founded2010
Employees
103
Employees103

MCRB Key Statistics

Market cap
145.75M
Market cap145.75M
Price-Earnings ratio
26.09
Price-Earnings ratio26.09
Dividend yield
Dividend yield
Average volume
44.53K
Average volume44.53K
High today
$16.42
High today$16.42
Low today
$15.77
Low today$15.77
Open price
$16.00
Open price$16.00
Volume
46.45K
Volume46.45K
52 Week high
$29.98
52 Week high$29.98
52 Week low
$6.53
52 Week low$6.53

Stock Snapshot

The current Seres Therapeutics(MCRB) stock price is $16.08, with a market capitalization of 145.75M. The stock trades at a price-to-earnings (P/E) ratio of 26.09.

During the trading session on 2026-01-14, Seres Therapeutics(MCRB) shares reached a daily high of $16.42 and a low of $15.77. At a current price of $16.08, the stock is +2.0% higher than the low and still -2.1% under the high.

Trading volume for Seres Therapeutics(MCRB) stock has reached 46.45K, versus its average volume of 44.53K.

Over the past 52 weeks, Seres Therapeutics(MCRB) stock has traded between a high of $29.98 and a low of $6.53.

Over the past 52 weeks, Seres Therapeutics(MCRB) stock has traded between a high of $29.98 and a low of $6.53.

People also own

Based on the portfolios of people who own MCRB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .